PMS2 and osteosarcoma: P/LP variants in genes that confer increased risk for the individual’s tumor type were also identified in patients with cancer types that are not frequently interrogated in traditional targeted GT models, such as 8.2% (6/73) of small bowel cancer patients having MLH1, MSH2, or PMS2 [40], 4.1% (6/145) of mesothelioma patients having BAP1 [41], 3.1% (3/96) of osteosarcoma patients having RB1 [42], and 2.5% (11/433) of soft tissue sarcoma patients having TP53 [43–45] P/LP variants.